Fractyl Health Inc GUTS.OQ GUTS.O is expected to show a fall in quarterly revenue when it reports results on March 3 (estimated) for the period ending December 31 2025
LSEG's mean analyst estimate for Fractyl Health Inc is for a loss of 18 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Fractyl Health Inc is $6.20, about 1,206.1% above its last closing price of $0.47
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.31 | -0.32 | -0.71 | Missed | -124.7 |
Jun. 30 2025 | -0.36 | -0.36 | -0.57 | Missed | -58.3 |
Mar. 31 2025 | -0.48 | -0.48 | -0.49 | Missed | -2.8 |
Dec. 31 2024 | -0.45 | -0.43 | -0.52 | Missed | -19.5 |
Sep. 30 2024 | -0.50 | -0.50 | -0.48 | Beat | 4 |
Jun. 30 2024 | -0.46 | -0.46 | -0.36 | Beat | 21.7 |
Mar. 31 2024 | -0.30 | -0.30 | -0.17 | Beat | 43.3 |
This summary was machine generated February 27 at 21:12 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)